Stem cell therapy fails to improve kidney rejection, raises safety flags
NCT ID NCT07005687
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a person's own stem cells (mesenchymal stem cells) could help treat chronic active antibody-mediated rejection in kidney transplant recipients. Only 3 patients were enrolled before the study was stopped early due to serious side effects. The treatment did not improve rejection, and one patient experienced severe complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC ACTIVE ANTIBODY-MEDIATED REJECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your gut bacteria change how transplant drugs work?
- Your gut bacteria might predict transplant rejection
- Engineered immune cells aim to trick the body into accepting a new kidney
- Massive data dive aims to outsmart kidney transplant rejection
- Smartphone Check-Ins could save transplanted kidneys
- Harmless virus levels may predict transplant complications